Free shipping on all orders over $ 500


Cat. No. M1808
Telaprevir Structure


Size Price Availability Quantity
5mg USD 108  USD120 In stock
10mg USD 162  USD180 In stock
50mg USD 468  USD520 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Telaprevir (VX-950) is a novel hepatitis C virus (HCV) NS3-4A protease inhibitor exhibits potent antiviral activities in HCV replicon cells. The NS3-4A serine protease of hepatitis C virus (HCV) is essential for viral replication and therefore has been one of the most attractive targets for developing specific antiviral agents against HCV. Telaprevir (VX-950) is currently in clinical development for the treatment of hepatitis C. Incubation with VX-950 resulted in a time- and dose-dependent reduction of HCV RNA and proteins in replicon cells. Moreover, following a 2-week incubation with VX-950, a reduction in HCV RNA levels of 4.7 log(10) was observed, and this reduction resulted in elimination of HCV RNA from replicon cells, since there was no rebound in replicon RNA after withdrawal of the inhibitor. The combination of VX-950 and alpha interferon was additive to moderately synergistic in reducing HCV RNA in replicon cells with no significant increase in cytotoxicity. The benefit of the combination was sustained over time: a 4-log(10) reduction in HCV RNA level was achieved following a 9-day incubation with VX-950 and alpha interferon at lower concentrations than when either VX-950 or alpha interferon was used alone. The combination of VX-950 and alpha interferon also suppressed the emergence of in vitro resistance mutations against VX-950 in replicon cells.

Cell Experiment
Cell lines Huh-7 cells
Preparation method Huh-7 cells harboring an autonomously replicating, subgenomic HCV replicon of the Con1 strain (19) were maintained in Dulbecco's modified Eagle's medium (DMEM), 10% heat-inactivated fetal bovine serum (FBS), 2 mM l-glutamine, and nonessential amino acids (JRH Biosciences, Lenexa, KS), plus 0.25 mg/ml G418 (Invitrogen, Carlsbad, CA). The subgenomic HCV replicon also encodes a neomycin phosphotransferase, which allows selective growth of HCV replicon-containing Huh-7 cells over HCV replicon-negative Huh-7 cells in the presence of G418. The VX-950 concentrations at which the HCV RNA level in the replicon cells is reduced by 50% (IC50) or by 90% (IC90) or the cell viability is reduced by 50% (CC50), were determined in HCV Con1 subgenomic replicon cells (19) using 4-parameter curve fitting (SoftMax Pro) as described previously (15, 18). Briefly, the replicon cells were incubated with compounds diluted in DMEM containing 2% FBS and 0.5% DMSO (without G418) at 37°C. Total cellular RNA was extracted using an RNeasy-96 kit (QIAGEN, Valencia, CA), and the copy number of the HCV RNA was determined in a quantitative, real-time, multiplex reverse transcription-PCR (QRT-PCR, or Taqman) assay (18). The cytotoxicity of compounds in the HCV replicon cells was measured under the same experimental settings using the tetrazolium-based cell viability assay as described before.
Concentrations 0, 0.03, 0.1, 0.3, 1, 3, 10 μ M
Incubation time 48 h
Animal Experiment
Animal models Mouse model for HCV NS3-4A serine protease
Formulation propylene glycol
Dosages 10, 25, 75, 150, or 300 mg/kg
Administration oral
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 679.85
Formula C36H53N7O6
CAS Number 402957-28-2
Purity >99%
Solubility DMSO
Storage at -20°C

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
Perni RB, et al. Antimicrob Agents Chemother. 2006 Mar;50(3):899-909. PMID: 16495249.

Related HCV Protease Products

Merimepodib, also known as VX-497, is an orally bioavailable IMPDH inhibitor with broad spectrum antiviral activities.

Inarigivir soproxil

Inarigivir soproxil, also known as SB 9200, is a novel agonist of innate immunity, which shows potent antiviral activity against resistant HCV variants.


Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5 and 366 pM against genotype 6a.


Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50 values of 1 and 0.21 nM for HCV 1a and 1b, respectively.


Block lipid transport-1 (BLT-1) is a specific inhibitor of the SR-BI (Scavenger receptor, class B, type I) mediated lipid transfer.

Abmole Inhibitor Catalog 2017

Keywords: Telaprevir, VX-950 supplier, HCV Protease, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.